NCT02177773 2019-11-12DOTA-TOCUniversity of California, San FranciscoPhase 1/2 Terminated300 enrolled 5 charts
NCT00947167 2017-03-03A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine TumorsStanford UniversityPhase 2 Terminated4 enrolled 5 charts